Novartis notified me about the ENACT program last week and this information was released today. It will provide expanded access to their new drug AMN107.
Rob
Novartis Launches Global Program Expanding Access to Investigational Compound Nilotinib (AMN107) for Patients With Hard-to-Treat Leukemia
--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------
You received this message because you are subscribed to the Google Groups "CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---
